Genmab — September 2020

[GeorgeBest]

Yes, Japan is very important, they don‘t give their teenage girls the hpv vaccine

[peter12]

On the latest fireside session JvdW said that Europe would require larger trials for TV

[Sukkeralf]

https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/

[Helge_LarsenPI-redaktør]

God morgen.

[transalp]

Go morgen..

[bibob]

God morgen.

[bibob]

Tisotumab på ESMO. https://www.onclive.com/view/tisotumab-vedotin-elicits-encouraging-responses-in-recurrent-metastatic-cervical-cancer?utm_source=sfmc&utm_medium=email&utm_campaign=9-21-20-_IMM-20-OGD0777_OncLiveSS_ESMO GLOBAL Conference Coverage eNews_Immunomedics_Trodelv&eKey=

[E_L]

same guy at youtube https://www.youtube.com/watch?v=ytGEecu6vrU

[E_L]

Stephen L. Hauser, MD: Ofatumumab in Treatment-Naïve Patients With MS https://www.youtube.com/watch?v=Uz7OUaCIyfU

[E_L]

Tisotumab data sets Seattle Genetics up for another approval, says Piper Sandler Piper Sandler analyst Joseph Catanzaro maintained a Neutral rating and $172 price target on SGen following the company's data from tisotumab's Phase II study in previously treated recurrent/metastatic cervical cancer at ESMO, which the analyst noted were "consistent with June's topline release." Catanzaro believes this data sets the company up for an "accelerated approval path in this setting for tisotumab."

[Helge_LarsenPI-redaktør]

Great. Thanks E L.

[Mogan]

God morgen

[E_L]

Blood Advances: Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma https://ashpublications.org/bloodadvances/article/4/18/4538/463776/Teclistamab-is-an-active-T-cell-redirecting

[E_L]

it seems I was correct that a decision on Camidanlumab had to be taken this summer:

[E_L]

ADCT looking to raise money again: ADC Therapeutics Announces Proposed Public Offering https://www.nasdaq.com/press-release/adc-therapeutics-announces-proposed-public-offering-2020-09-21

[E_L]

which means we get a SEC report : https://sec.report/Document/0001140361-20-020981/#nt10014672x2_f1.htm

[E_L]

where on p6 it reads "Our collaboration and license agreement with Genmab may require a divestment of Cami, in which Genmab has a 25% interest. On June 24, 2020, we and Genmab agreed to enter into a period of good faith negotiations regarding the key financial terms of our license agreement. " etc etc

[E_L]

this may be a good Cami summary: "we are evaluating Cami in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL and have enrolled 47 patients as of June 30, 2020.

[E_L]

We have completed enrollment of a 133-patient Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL that has shown an 86.5% ORR and a 48.6% CRR in patients with HL at the initial dose for our pivotal Phase 2 clinical trial and a 44.0% ORR and an 8.0% CRR in a subset of patients with T-cell lymphoma as of April 2019.

[E_L]

We anticipate reporting top-line response rate data from our pivotal Phase 2 clinical trial of Cami for the treatment of HL in the first half of 2021, and we believe that this clinical trial, if successful, will support a BLA submission.